However, in whole‐AML cases, patients with DOK6 promoter methylated had a significantly longer OS than those without DOK6 promoter methylated (mean 23.10 vs 14.20 months; P = .042; Figure 3A). This evidence concerns the gene DOK6 and acute myeloid leukemia.